Predemtec GmbH, a Hennigsdorf (near Berlin), Germany-based developer of a blood test for a reliable diagnosis of Alzheimer’s disease, received a seed financing of undisclosed amount.
High-Tech Gruenderfonds made the investment.
The company will use the funds to finalize the first test into a marketable product and to expand the scope of the test towards early diagnosis.
Founded in September 2011 by Dr. Patrick Scotton, CEO, and Ms Dr. Annegret Feuerhelm-Heidl, CSO/managing director, Predemtec develops a test which allows to diagnose Alzheimer’s disease with a specificity and sensitivity of over 90% by means of immunological detection of 6 different blood biomarkers. The biomarker set is prevalidated and patented while clinical trials for the biomarkers’ validation on secured Alzheimer patients and for the early diagnosis of MCI patients (mild cognitive impairment) are under way.